Navigation Links
Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40.
Date:7/24/2014

A replay of the call will be available from 7/24/2014 to 8/01/2014.  For the replay, please call (855) 859-2056 (Domestic) or (404) 537-3406 (International) and use Conference ID 22676336 or go to http://investor.sigmaaldrich.com/ under "Presentations & Events."

Cautionary Statement:  This release contains forward-looking statements.  Such statements involve risk and uncertainty, including financial and business environment risks and projections.  Such statements include those preceded or followed by, or including the words, "expect," "expects," "expected," "better," "could," "approximately," "would," "likely," "will," or similar expressions, and other statements contained herein regarding matters that are not historical facts.  Additionally, this release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including, without limitation, statements with respect to the Company's expectations, goals, beliefs, intentions and the like regarding future sales, earnings, return on equity, return on invested capital, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions and other matters.  These statements are based on assumptions regarding the Company's operations, investments and acquisitions and conditions in the markets the Company serves.  While the Company believes these statements are reasonable, such statements are subject to risks and uncertainties, including, among others, certain economic, political and technological factors.  Actual results could differ materially from those stated or implied in this release, due to, but not limited to, such factors as (1) global economic conditions and other factors affecting the creditworthiness of our customers around the world, (2) changes in pricing and the competitive environm
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
2. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
3. Sigma-Aldrich Corporation To Present At Upcoming Investor Conferences
4. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
5. Sigma-Aldrich (NASDAQ: SIAL) Declares $0.20 Quarterly Dividend
6. Sigma-Aldrich Aligns Into Three New Market-Focused Business Units
7. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
8. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
9. Sigma-Aldrich Announces Q1 2013 Earnings Conference Call
10. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2013 Sales And EPS Of $675 Million And $1.01, Respectively, Both Record Quarterly Highs. Reaffirms Full Year 2013 Diluted Adjusted EPS Outlook Of $4.10 To $4.20.
11. Sigma-Aldrich Corporation Declares $0.215 Per Share Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... to developing products that address unmet medical needs in ... that its President and Chief Executive Officer, Christopher ... at the 27 th Annual ROTH Conference in ... March 10, 2015 at 1:00 PM Pacific Daylight Time ...
(Date:3/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5sqnn3/global_rising ) has ... Outlook 2015" report to their offering. ... after with fresh vigor as new targets , approaches ... to bring a paradigm change in the way diseases ... cell therapy/Regenerative Medicine space. The number of ...
(Date:3/5/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... announced today that Atlanta -based Shepherd ... spinal cord injury and brain injury, has commenced enrollment ... progenitor cells) in newly injured patients with sensory and ... The Phase 1/2a trial follows the successful completion ...
Breaking Medicine Technology:Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3Global Pharma Rising Stars Outlook 2015 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4
... April 10 Napo,Pharmaceuticals, Inc., (LSE: NAPL and ... a successfully completed Phase 2 trial for CRO-ID,(crofelemer ... conducted,by its partner, Glenmark Pharmaceuticals Limited (BSE: Glenmark). ... duration of diarrhea,stool frequency and stool consistency; additional ...
... Calif., April 10 MannKind,Corporation (Nasdaq: MNKD ... announcement by Pfizer Inc. that over the course ... patients treated with Exubera developed lung,cancer, although Pfizer ... whether this observation was related to Exubera. According ...
Cached Medicine Technology:Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 2Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 3Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 4Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 5MannKind Addresses Pfizer's Announcement Regarding Exubera 2MannKind Addresses Pfizer's Announcement Regarding Exubera 3
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... California (PRWEB) March 05, 2015 ... last week released a special issue ... the field of PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders ... Syndromes), an autoimmune reaction triggered by infections such ... which result in inflammation of the child's brain. ...
(Date:3/5/2015)... March 05, 2015 Wimbledon Health ... provides vascular, echocardiogram and NCV testing, announced ... the Chief Medical Officer. Dr. Artel will be responsible ... of the WimbledonMED program and the continued growth and ... about working with Wimbledon Health Partners as a consulting ...
(Date:3/5/2015)... March 5, 2015 – As National Patient Safety Awareness ... children’s hospitals around the country are affirming the critical ... safe as possible for their children. , A national ... Safety (SPS) and the Children’s Hospital Association—are collaborating to ... the hospital with their child. , “SPS is ...
(Date:3/5/2015)... The MTC 5-day Fundamental Implantology Course has ... a variety of dental disciplines, to offer implant placement ... the onset we wanted this course to be a ... the excellence of the lecturers and the sheer energy ... than satisfied our aims." , Unlike large-scale training ...
Breaking Medicine News(10 mins):Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 2Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 4Health News:MIS Global Training Center (MTC) Launches its Fundamental Implantology Course for Doctors - with a Difference 2
... Creates ... ... (Vocus) April 14, 2010 -- PMSI , one of the nation’s largest providers ... the nation’s leader in pain medication monitoring solutions, today announced a strategic partnership to ...
... in Alaska have discovered that lingering oil from the 1989 ... more than 20 years after the disaster. The research, published ... reveal long-term exposure to oil in harlequin ducks and demonstrates ... than years. The Exxon Valdez tanker ran aground on ...
... ... by HealthGrades, April 8, at the 2010 DTC National Conference. , ... Florham Park, N.J. (PRWEB) April 14, ... company for direct-to-consumer (DTC) marketing, today announced the winners of the 10th annual ...
... therapy, study found , WEDNESDAY, April 14 (HealthDay News) ... for developing blood clots, especially if they,re undergoing hormone ... it is important to consider thromboembolic [blood-clotting] side effects ... require endocrine treatment," said Mieke van Hemelrijck, lead author ...
... ... , ... 14, 2010 -- Tahitian Noni International (TNI) announced that just one month after ... have increased dramatically. Sales in North America have skyrocketed, and double digit growth was common ...
... ... Living Green and “Tip of the Day” at www.greenearthcleaning.com , featuring 365 easy ways ... ... environmentally friendly dry cleaning, GreenEarth Cleaning, LLC announced today the launch of a new feature ...
Cached Medicine News:Health News:PMSI and Ameritox Launch Program to Enhance Quality and Effectiveness of Opioid Therapy 2Health News:PMSI and Ameritox Launch Program to Enhance Quality and Effectiveness of Opioid Therapy 3Health News:Wildlife still exposed to Exxon Valdez oil 20 years after disaster 2Health News:2010 DTC National Advertising Award Winners Honored 2Health News:2010 DTC National Advertising Award Winners Honored 3Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 2Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 3Health News:Worldwide Sales in March Increase Dramatically At Tahitian Noni International 2Health News:GreenEarth Makes Every Day Earth Day with New Online Tools to Live a Greener Life 2Health News:GreenEarth Makes Every Day Earth Day with New Online Tools to Live a Greener Life 3
... Loading Units With Titanium Staples ... TA™ (Single Use Reloadable Stapler ... Auto Suture™ PREMIUM MULTIFIRE TA™ ... gynecological, pediatric and thoracic surgical ...
... Single Use Loading Units ... Series™ (Single Use Reloadable Staplers ... Auto Suture™ TA™ Reloadable staplers ... pediatric and thoracic surgical procedures ...
... Single Use reloadable linear stapler for resection, ... ,The Auto Suture™ MULTIFIRE GIA™ 60 and ... GIA™ 60 and 80 single use loading ... 60 knifeless single use surgical stapler with ...
... with titanium staples and in-line handle., ... use in the resection or transection of ... a double staggered row (or triple staggered ... of titanium staples and is available in ...
Medicine Products: